Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SynAct Pharma AB ( (SE:SYNACT) ) has provided an update.
SynAct Pharma has initiated a Phase 2 randomized, double-blind, placebo-controlled multicenter study, RESPIRE (SynAct-CS009-RESPIRE), to evaluate resomelagon in 96 patients hospitalized with respiratory insufficiency due to viral infections such as Covid-19, influenza, or RSV. Building on earlier clinical and preclinical data suggesting faster recovery, reduced intensive care needs, and mortality benefits, the trial aims to show that resomelagon can reduce severe outcomes including death, mechanical ventilation, organ support, and renal failure, thereby expanding the drug’s potential use in the hospital setting and strengthening SynAct’s dual development strategy across autoimmune disease and acute viral hyperinflammation.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK25.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that focuses on resolution therapy to treat inflammatory and autoimmune conditions. Its lead drug candidate, resomelagon (AP1189), is being developed for rheumatoid arthritis and other autoimmune diseases, as well as for host-directed treatment of severe viral infections that cause hyperinflammation and respiratory complications in hospitalized patients.
Average Trading Volume: 127,118
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.2B
Learn more about SYNACT stock on TipRanks’ Stock Analysis page.